Updated:
Belite Bio
Belite Bio is a clinical-stage biotech led by Tom Lin, focused on Tinlarebant for Stargardt disease and dry AMD.
Belite Bio
Founded in 2018 by Tom Lin, Belite Bio operates as a clinical-stage biotech focused on developing treatments for degenerative retinal diseases. The firm is structured around Tinlarebant, an oral retinol-binding protein 4 antagonist. The underlying premise targets the accumulation of toxic vitamin A byproducts in the eye, a pathway linked to Stargardt disease and geographic atrophy in dry age-related macular degeneration. Belite Bio raised approximately $92 million through its IPO and concurrent private placements in April 2022, and its primary operations span San Diego and Hong Kong. The firm's pipeline concentrates on Tinlarebant across multiple indications. The lead program for Stargardt disease — a rare, inherited condition causing vision loss in children and young adults — entered a pivotal Phase 3 trial (DRAGON). A second Phase 3 trial (PHOENIX) is evaluating Tinlarebant for geographic atrophy secondary to dry AMD, a much larger market with significant unmet need. The company has reported positive interim data for both programs and is actively enrolling patients across sites in the United States, Europe, and Asia. Investment reasoning hinges entirely on a single-molecule, multi-indication strategy. Belite Bio maintains a lean public-company team with its executive leadership based largely in the US and strategic operations in Hong Kong. The firm is backed by a syndicate of healthcare-focused institutional investors. In April 2024, the company announced clinical updates to both Phase 3 trials, reinforcing its timelines for topline data expected in late 2024 and 2025. This firm's structure separates it from typical venture-funded biotechs. It is an operating company publicly listed on Nasdaq (BLTE) rather than a family office or investment fund. That public-market access provides liquidity and capital-raising options unavailable to private peers, in exchange for the scrutiny and volatility that come with binary clinical-stage drug development.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Additional offices
Hong Kong
Principals
Tom Lin
Chairman and CEO
Nathan Mata
Chief Scientific Officer
Sector focus
Frequently asked questions
What is Belite Bio's lead drug candidate?
Tinlarebant (LBS-008) is a once-daily oral retinol-binding protein 4 antagonist designed to reduce the accumulation of cytotoxic vitamin A byproducts in the retina. It is the sole drug candidate in the firm's pipeline, being tested in two separate Phase 3 trials for Stargardt disease and geographic atrophy.
How is Belite Bio funded?
Belite Bio went public on the Nasdaq in April 2022. The IPO and accompanying private placements raised roughly $92 million, and the company is also backed by healthcare-specialist institutional investors. As a public company, it funds operations primarily through equity offerings.
What distinguishes Belite Bio's approach to Stargardt disease?
Belite Bio seeks to address the condition with a systemic oral therapy rather than an injected or gene-based treatment. Most competitors in the Stargardt space require frequent ocular injections or genetic modification. A functional oral medication would represent a significant departure in standard of care, though the approach carries distinct safety and bioavailability challenges.
Where are Belite Bio's clinical trials being conducted?
The firm actively recruits patients across a global network of trial sites. Its operations and investigator footprint stretch across the United States, Europe, and Asia, with corporate presence in San Diego and Hong Kong.
Is Belite Bio a family office or an operating biotech?
Belite Bio is a publicly traded clinical-stage biotech company, not a family office or investment firm. Its capital goes toward the clinical development of its own drug pipeline, not toward outside investments or fund commitments.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: